A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3044-3044 ◽  
Author(s):  
B. Besse ◽  
J. Soria ◽  
C. Gomez-Roca ◽  
J. A. Ware ◽  
A. A. Adjei ◽  
...  
Lung Cancer ◽  
2014 ◽  
Vol 85 (2) ◽  
pp. 245-250 ◽  
Author(s):  
Julian R. Molina ◽  
Nathan R. Foster ◽  
Thanyanan Reungwetwattana ◽  
Garth D. Nelson ◽  
Andrew V. Grainger ◽  
...  

MedChemComm ◽  
2017 ◽  
Vol 8 (10) ◽  
pp. 1914-1918
Author(s):  
Lian-Xiang Luo ◽  
Ying Li ◽  
Yu-Zhen Niu ◽  
Yu-Wei Wang ◽  
Qian-Qian Wang ◽  
...  

Herein, we reported 5067-0952, a potent ALK inhibitor with pharmacological efficacy in non-small cell lung cancers harboring the ALK fusion oncogene.


2012 ◽  
Vol 66 (3) ◽  
pp. 221-227 ◽  
Author(s):  
Xueying Yang ◽  
Jing Di ◽  
Yang Zhang ◽  
Suning Zhang ◽  
Jibin Lu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document